VTVT vTv Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, vTv Therapeutics Inc reported revenue of $0, net income of −$13.1M and diluted EPS of n/a; over the last four quarters revenue was $36.8M and net income −$4.76M; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
VTVT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$32.8M, net income −$27.0M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue $1.02M, gross profit n/a, operating income −$24.2M, net income −$18.5M (margin -1815.3%), EPS n/a
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$25.5M, net income −$20.3M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue $2.02M, gross profit n/a, operating income −$22.5M, net income −$19.2M (margin -949.7%), EPS n/a
- Fiscal year ended Dec 2021: revenue $4.01M, gross profit n/a, operating income −$21.7M, net income −$13.0M (margin -324.3%), EPS n/a
VTVT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$13.1M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $36.8M, net income $24.1M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (down 100.0% year over year), net income −$7.14M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $0, net income −$8.70M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0, net income −$6.05M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$5.09M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $17.0K, net income −$3.63M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $0, net income −$4.78M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $0, net income −$5.18M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $1.00M, net income −$4.87M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income −$3.48M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $0, net income −$6.65M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$5.62M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$4.50M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $9.00K (up 0.0% year over year), net income −$4.75M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$4.26M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $9.00K (up 0.0% year over year), net income −$3.15M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $2.00M (up 102.6% year over year), net income −$7.01M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $9.00K, net income −$7.05M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $3.00M, net income −$1.09M, EPS n/a
VTVT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$25.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$25.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$19.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$16.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$19.3M, share buybacks n/a
VTVT balance sheet
- Jun 30, 2026: cash $86.6M, total assets $87.6M, total liabilities $8.96M, shareholders' equity $78.6M
- Mar 31, 2026: cash $98.1M, total assets $98.8M, total liabilities $8.85M, shareholders' equity $90.0M
- Dec 31, 2025: cash $88.9M, total assets $89.9M, total liabilities $25.5M, shareholders' equity $64.4M
- Sep 30, 2025: cash $98.5M, total assets $99.5M, total liabilities $29.0M, shareholders' equity $70.5M
- Jun 30, 2025: cash $25.9M, total assets $26.4M, total liabilities $24.0M, shareholders' equity $2.76M
- Mar 31, 2025: cash $31.1M, total assets $32.0M, total liabilities $23.1M, shareholders' equity $7.92M
- Dec 31, 2024: cash $36.7M, total assets $38.3M, total liabilities $24.0M, shareholders' equity $12.2M
- Sep 30, 2024: cash $41.6M, total assets $43.2M, total liabilities $25.3M, shareholders' equity $15.0M
What is VTVT's revenue?
vTv Therapeutics Inc reported $36.8M of revenue over its last four quarters, through June 30, 2026.
Is VTVT profitable?
No. vTv Therapeutics Inc lost $4.76M over the last four quarters.